Clinical trials: Adnexal Tumor
Relapsed Ovarian Cancer
Reprab Study: PLD + Trabectedin Rechallenge
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL
- Trial name
- MITO36 (NCT04887961)
- Testing
- PLD and Trabectedin rechallenge
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Polycystic Ovary Syndrome
L-Carnitine and Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome
The purpose of the study to assess the efficacy of adding L-carnitine to clomiphene citrate for increasing the ovulation and the pregnancy rate in women with PCOS.
- Trial name
- NCT03476356
- Testing
- oral clomiphene citrate, oral carnitine supplementation
- Where
- Egypt
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Metastatic Cancer, Metastatic Breast Cancer
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer.
- Conditions
- Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer
- Trial name
- CHANCES (NCT05143970)
- Testing
- IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Institut Paoli-Calmettes
Hereditary Breast and Ovarian Cancer
Cancer Genetics Hereditary Cancer Panel Testing
This study is about understanding the use of a genetic test (Myriad Genetics myRisk panel) that analyzes 25 genes related to different hereditary cancer conditions.
- Trial name
- HCP (NCT02324062)
- Testing
- Questionnaires, Blood Draw and Baseline Questionnaire
- Where
- 2 sites in United States
- Volunteers
- 1,511 people
- Sponsor
- University of Southern California
Ovarian Cancer, Quality of Life
Patient Preferences for Precision Medicine: Determining Optimal Patient Quality of Life Using PARPi's
Patients with ovarian cancer with defective DNA repair mechanisms derive substantial benefit from PARP inhibitor (PARPi) maintenance therapy.
- Trial name
- 4PDQ (NCT06751303)
- Testing
- Patients that are HRP are given a decision aid for PARPi use
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of Saskatchewan
Ovarian Neoplasms
Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting
Four phase III trials in ovarian cancer consistently showed that front-line poly(ADP-ribose) polymerase (PARP) inhibition can significantly improve progression-free survival.
- Trial name
- NCT05153603
- Testing
- Olaparib mono-maintenance therapy
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ovarian Cancer, Fallopian Tube Cancer
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
This study will look at the efficacy and safety of weekly administration of paclitaxel (Taxol®) in monotherapy compared to paclitaxel in combination with topotecan or carboplatin in patients with ovarian cancer in early relapse.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Malignant Tumor of Peritoneum
- Trial name
- NCT00189566
- Testing
- Paclitaxel, Topotecan, Carboplatin
- Where
- France
- Volunteers
- 165 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Cancer
METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer
To further evaluate and observe the efficacy and safety of solantinib combined with METR-NK neoadjuvant therapy for advanced epithelial ovarian cancer in patients with advanced epithelial ovarian cancer by using solantinib…
- Trial name
- NCT06884345
- Testing
- METR-NK cells combined with Solvatinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Anhui Provincial Cancer Hospital
Ovarian Cancer
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer .
- Trial name
- NCT03940196
- Testing
- NovoTTF-100L(O), Paclitaxel
- Where
- 119 sites in United States, Austria and 11 more
- Volunteers
- 540 people
- Sponsor
- NovoCure Ltd.
Ovarian Cancer
FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer
RATIONALE: FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with relapsed or refractory advanced…
- Trial name
- NCT00085527
- Testing
- depsipeptide
- Where
- United States
- Sponsor
- University of Chicago
Ovarian Cancer, Fallopian Tube Cancer
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer
The purpose of this trial is to assess the effectiveness of TroVax® compared to placebo in extending the time to progression in patients with asymptomatic relapsed platinum resistant ovarian, fallopian tube or primary peritoneal…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- TRIOC (NCT01556841)
- Testing
- TroVax®
- Where
- 12 sites in United Kingdom
- Volunteers
- 94 people
- Sponsor
- University College, London
Ovarian Cancer
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
The purpose of this study is to determine whether the investigational drug catumaxomab delivered in the planned treatment schedule is a safe and effective treatment for women with advanced ovarian cancer who experience a complete…
- Trial name
- NCT00377429
- Testing
- catumaxomab
- Where
- 12 sites in United States
- Volunteers
- 47 people
- Sponsor
- Neovii Biotech
Polycystic Ovary Syndrome, Cardiovascular Disease
LIPT - Liraglutide in Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.
- Trial name
- LIPT (NCT02073929)
- Testing
- Liraglutide for 26 weeks
- Where
- 3 sites in Denmark
- Volunteers
- 72 people
- Sponsor
- Jens Faber
Ovarian Cancer
Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation
The "Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation" study is open to a subset of patients with disorders of sex development (DSD) which is associated with the risk of malignancy and a high risk of…
- Trial name
- NCT06518746
- Testing
- Cryopreservation of gonadal tissue
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Ovarian Neoplasms
A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin
The objectives of this study are to determine the response rate to 9-AC in patients with advanced ovarian cancer who have recurrent disease after paclitaxel- and cisplatin-based chemotherapy regimens.
- Trial name
- NCT00001427
- Testing
- 9-aminocamptothecin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
This trial studies the chemotherapy toxicity on quality of life in older patients with stage I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.
- Conditions
- Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7
- Trial name
- NCT01366183
- Testing
- Assessment of Therapy Complications, Carboplatin, Filgrastim
- Where
- 357 sites in United States
- Volunteers
- 290 people
- Sponsor
- Gynecologic Oncology Group
PCOS- Polycystic Ovary Syndrome
The Synbiotics Effects in Polycystic Ovary Syndrome: A Randomized Controlled Trial
The goal of this clinical trial is to compare the effect of synbiotics and placebo in Thai women with polycystic ovary syndrome.
- Trial name
- PCOS (NCT06169566)
- Testing
- synbiotics
- Where
- Thailand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Maharaj Nakorn Chiang Mai Hospital
Breast Cancer, Gastric Cancer
Biological Therapy in Treating Patients With Advanced Cancer
RATIONALE: A person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Gastric Cancer, Ovarian Cancer
- Trial name
- NCT00005956
- Testing
- HER-2/neu intracellular domain protein, therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Polycystic Ovary Syndrome
Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome
The investigators hypothesis is that free fatty acids (FFA) accumulation in non fatty tissues would lead to insulin resistance and hyperandrogenism in PCOS women.
- Trial name
- NCT01019356
- Testing
- Rosiglitazone, Acarbose
- Where
- Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jean-Patrice Baillargeon
Fallopian Tube Cancer, Ovarian Cancer
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sometimes after treatment, the tumor may not need additional treatment until it progresses.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00263822
- Testing
- erlotinib hydrochloride
- Where
- 92 sites in Australia, Austria and 6 more
- Volunteers
- 835 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.